

PATENT ASSIGNMENT

Electronic Version v1.1
Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Enzon Pharmaceuticals, Inc.	01/29/2010
RECEIVING PARTY DATA	
Name:	Defiante Farmaceutica, S.A.
Street Address:	Rua da Alfandega, no 78, 3
City:	Funchal
State/Country:	PORTUGAL
Postal Code:	9000-059
PROPERTY NUMBERS Total: 11	
Property Type	Number
Patent Number:	5616334
Patent Number:	6406713
Patent Number:	5100591
Patent Number:	6689762
Application Number:	11759988
Application Number:	12105682
Application Number:	11965939
Application Number:	12105913
Patent Number:	7584675
Application Number:	12344070
Application Number:	61244280
CORRESPONDENCE DATA	
Fax Number:	(949)567-6710
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	949-567-6700

CH \$440.00 5616334

501094154

PATENT
REEL: 023937 FRAME: 0530

Email: ipprosecution@orrick.com
Correspondent Name: Orrick, Herrington & Sutcliffe, LLP
Address Line 1: 4 Park Plaza, Suite 1600
Address Line 2: IP Prosecution Department
Address Line 4: Irvine, CALIFORNIA 92614-2558

ATTORNEY DOCKET NUMBER:	20022.5
-------------------------	---------

NAME OF SUBMITTER:	Angela Wendel
--------------------	---------------

Total Attachments: 11
source=Patent Assignment#page1.tif
source=Patent Assignment#page2.tif
source=Patent Assignment#page3.tif
source=Patent Assignment#page4.tif
source=Patent Assignment#page5.tif
source=Patent Assignment#page6.tif
source=Patent Assignment#page7.tif
source=Patent Assignment#page8.tif
source=Patent Assignment#page9.tif
source=Patent Assignment#page10.tif
source=Patent Assignment#page11.tif

ASSIGNMENT OF PATENTS

This ASSIGNMENT OF PATENTS (this "Assignment"), dated as of January 29, 2010, is entered into by and between Enzon Pharmaceuticals, Inc., a Delaware corporation ("Assignor"), and Defiante Farmacêutica, S.A., a company organized under the laws of Portugal ("Assignee").

WHEREAS, Assignor and Assignee are party to the Asset Purchase Agreement, dated as of November 9, 2009, by and between Klee Pharmaceuticals, Inc., a Delaware corporation, Assignee and Sigma-Tau Finanziaria S.p.A., an Italian corporation (solely for the purposes set forth therein), on the one hand, and Assignor, on the other hand (the "Asset Purchase Agreement");

WHEREAS, pursuant to the Asset Purchase Agreement, Assignor has agreed to sell, convey, assign, transfer and deliver to the Assignee, and Assignee has agreed to purchase, acquire, receive and accept from Assignor, all of Assignor's right, title and interest in and to the issued patents and patents applications listed on Schedule A hereto and the inventions disclosed therein (collectively, the "Patents") among other Assets (as defined in the Asset Purchase Agreement); and

WHEREAS, Assignor desires to sell, convey, assign, transfer and deliver to Assignee, and Assignee desires to purchase, acquire, receive and accept from Assignor, all of Assignor's right, title and interest in and to the Patents.


NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor does hereby sell, convey, assign, transfer and deliver to Assignee, its successors and assigns, the full and exclusive right, title and interest in and to the Patents or applications thereof, not only in the United States and its territorial possessions, but in all countries foreign thereto to be obtained for the Patents, and to any continuation, continuation-in-part, division, renewal, extension or reissue thereof or any legal equivalent thereof, and all causes of actions, claims and demands for, or arising from, any present or future infringement or other violation of the Patents, including any and all rights to sue for past infringement occurring prior to the date hereof, and to collect damages therefor, in the United States or a country foreign thereto for the full term or terms for which the same may be granted, including all priority rights under the International Convention.

Assignor authorizes and requests the United States Commissioner of Patents and Trademarks and any officials of governmental or administrative office in any country whose duty it is to record patent assignments as aforesaid, to record Assignee as owner of the Patents in accordance with the terms of this Assignment and hereby transfers the entire right, title and interest in, to and under the same, for the sole use and enjoyment of Assignee, its successors, assigns or other legal representatives.

[Execution page follows.]

IN WITNESS WHEREOF, Assignor and Assignee have caused this Assignment to be executed by their respective officers thereunto duly authorized as of the date first written above.

ENZON PHARMACEUTICALS, INC.

By: 
Name: Craig A Toman
Title: EVP & CFO

DEFIANTE FARMACÊUTICA, S.A.

By: _____
Name:
Title:

[Signature Page to Patent Assignment]

IN WITNESS WHEREOF, Assignor and Assignee have caused this Assignment to be executed by their respective officers thereunto duly authorized as of the date first written above.

ENZON PHARMACEUTICALS, INC.

By: _____
Name:
Title:

DEFIANTE FARMACÊUTICA, S.A.

By:  _____
Name: Paulo Viegas
Title: CEO

State of New Jersey)
) ss:
County of Somerset)

On this 29 day of January, 2010 before me, the undersigned, personally appeared Craig A. Tooman, personally known to me or proved to me on the basis of satisfactory evidence to be the person who executed this instrument on behalf of ENZON PHARMACEUTICALS, INC., and acknowledged that s/he executed it in such representative capacity.

IN WITNESS WHEREOF, I have hereunto set my hand and official seal.

Carol A. Smith
Notary Public

Carol A. Smith
Notary Public
ID #2321419
State of New Jersey
My Commission Expires 11/4/2014

State of New York)
) ss:
County of New York)

On this 27 day of January, 2010 before me, the undersigned, personally appeared Paulo Viegas, personally known to me or proved to me on the basis of satisfactory evidence to be the person who executed this instrument on behalf of DEFIANTE FARMACÊUTICA, S.A., and acknowledged that s/he executed it in such representative capacity.

IN WITNESS WHEREOF, I have hereunto set my hand and official seal.



Notary Public

DESIREE J. RIGILANO
Notary Public, State of New York
No. 01R16123899
Qualified in New York County
Commission Expires March 14, 2013

SCHEDULE A

IR	FTL	SBJ	STAT	APNO	COUN	APDA	PATNO	PATDA	COMMENTS
1.	2002-15	ABLC	G	08/430,699	US	4/28/1995	5,616,334	4/1/1997	
2.	2002-15-CA	ABLC	G	1338701	CA	02/29/1988	1,338,701	11/12/1996	
3.	2002-15-JP	ABLC	G	0504538	JP	3/3/1988	2,705,175		Expired
4.	2002-16	ABLC	G	07/364,481	US	6/8/1989	4,973,465	11/27/1990	Expired
5.	2002-16-CA	ABLC	G	1338736	CA	12/1/1987	1,338,736	11/26/1996	
6.	2002-16-JP	ABLC	G	62-307342	JP	12/4/1987	2,852,421		Expired
7.	2002-17	ABLC	G	08/430,661	US	4/28/1995	6,406,713	6/18/2002	
8.	2002-18	ABLC	G	07/582,053	US	9/14/1990	5,100,591	3/31/1992	
9.	2002-18-CA	ABLC	G	2,025,298	CA	9/13/1990	2,025,298	5/10/2005	
10.	2002-18-JP	ABLC	G	02/245991	JP	9/14/1990	2,831,455	9/25/1998	
11.	2003-07-PCT	PEG-ASP	F	PCT/US99/02480	WO	8/6/1999	WO99/39732	8/12/1999	Expired

IR	TI	SBJ	STAT	APNO	COIN	APDA	PATNO	PATDA	COMMENTS
12.	2003-07-PCT-EP1-IT	PEG-ASP	G	99-906749.9	IT	2/9/1999	1053012	7/23/2003	
13.	2003-07-U	PEG-ASP	G	09/370,390	US	8/6/1999	6,689,762	2/10/2004	
14.	2005-11-P	ASP	X	60/817,817	US	6/30/2006			Expired
15.	2005-11-PCT-AU	ASP	F	PCT/US07/70706 2007/275535	AU	6/8/2007			
16.	2005-11-PCT-CA	ASP	F	PCT/US07/70706 2652718	CA	6/8/2007			
17.	2005-11-PCT-CN	ASP	F	PCT/US07/70706 2007/80024860.7	CN	6/8/2007			
18.	2005-11-PCT-EP	ASP	F	07840229.4	EP	6/8/2007			
19.	2005-11-PCT-IL	ASP	F	195168	IL	6/8/2007			
20.	2005-11-PCT-IN	ASP	F	PCT/US07/70706	IN	6/8/2007			
21.	2005-11-PCT-JP	ASP	F	PCT/US07/70706	JP	6/8/2007			
22.	2005-11-PCT-KR	ASP	F	10-2008-7028792	KR	6/8/2007			
23.	2005-11-PCT-MX	ASP	F	MX/A/2009/000284	MX	6/8/2007			

822841.4A-New York Server 4A - MSW
OHS East:160615424.10

IR	TYT	SBJ	STAT	APNO	COIN	APDA	PATNO	PATDA	COMMENTS
24.	2005-11-PCT-NZ	ASP	F	572519	NZ	6/8/2007			
25.	2005-11-TW	ASP	F	96123026	TW	6/26/2007			
26.	2005-11-U	ASP	F	11/759,988	US	6/8/2007			
27.	2005-11-U-PCT	ASP	F	PCT/US07/70706	WO	6/8/2007	WO08/11234	1/24/2008	Expired
28.	2006-06-P	ADA	X	60/913,039	US	4/20/2007			Expired (provisional)
29.	2006-06-PCT	ADA	F	PCT/US08/60733	WO	4/18/2008	WO08/131163	10/30/2008	Expired
30.	2006-06-PCT-AU	ADA	F	2008242791	AU	4/18/2008			
31.	2006-06-PCT-EP	ADA	F	08754910.1	EP	4/18/2008-INT 11/18/2009			
32.	2006-06-PCT-JP	ADA	F	PCT/US08/60733	JP	4/18/2008-INT 10/20/2009			
33.	2006-06-PCT-BR	ADA	F	PCT/US08/60733	BR	4/18/2008-INT			
34.	2006-06-PCT-CA	ADA	F	2684749	CA	4/18/2008-INT 10/20/2009			
35.	2006-06-PCT-MX	ADA	F	PCT/US08/60733	MX	4/18/2008-INT			

IR	YTI	SEI	STAT	APNO	COIN	APDA	PATNO	PATDA	COMMENTS
36. 2006-06-PCT-NZ	Enzymatic Anticancer Therapy	ADA	F	580980	NZ	4/18/2008-INT 11/06/2009			
37. 2006-06-PCT-KR	Enzymatic Anticancer Therapy	ADA	F	10-2009-7023239	KR	4/18/2008-INT 11/06/2009			
38. 2006-06-PCT-IN	Enzymatic Anticancer Therapy	ADA	F	1927/MUMNP/2009	IN	4/18/2008-INT			
39. 2006-06-PCT-IL	Enzymatic Anticancer Therapy	ADA	F	201593	IL	4/18/2008-INT			
40. 2006-06-PCT-CN	Enzymatic Anticancer Therapy	ADA	F	PCT/US08/60733	CN	4/18/2008-INT			
41. 2006-06-PCT-RU	Enzymatic Anticancer Therapy	ADA	F	2009142817	RU	4/18/2008-INT 11/19/2009			
42. 2006-06-TW	Enzymatic Anticancer Therapy	ADA	F	97114405	TW	4/21/2008			
43. 2006-06-U	Enzymatic Anticancer Therapy	ADA	F	12/105,682	US	4/18/2008			
44. 2006-24-P	Use of Adenosine Deaminase for Treating Pulmonary Disease	ADA	X	60/882,748	US	12/29/2006			Expired (provisional)
45. 2006-24-PCT	Use of Adenosine Deaminase for Treating Pulmonary Disease	ADA	F	PCT/US07/89085	WO	12/28/2007	WO08/83302	7/10/2008	Expired
46. 2006-24-PCT-CA	Use of Adenosine Deaminase for Treating Pulmonary Disease	ADA	F	PCT/US07/089085 2671209	CA	12/28/2007			
47. 2006-24-PCT-EP	Use of Adenosine Deaminase for Treating Pulmonary Disease	ADA	F	PCT/US07/089085 070870057	EP	12/28/07			

IR	Y11	SB3	STAT	APNO	CCUN	APDA	PATNO	PATDA	COMMENTS
48.	2006-24-PCT-JP	ADA	F	PCT/US07/089085	JP	12/28/07			
49.	2006-24-1W	ADA	F	96150708	TW	12/28/2007			
50.	2006-24-U	ADA	F	11/965,939	US	12/28/2007			
51.	2007-01-P	ADA	X	60/913,009	US	4/20/2007			Expired (provisional)
52.	2007-01-PCT	ADA	F	PCT/US08/60805	WO	4/20/2008	WO08/131208	10/3/2008	
53.	2007-01-PCT-AU	ADA	F	2008242748	AU	4/18/2008-INT			
54.	2007-01-PCT-EP	ADA	F	08746255.2	EP	4/18/2008-INT 11/18/2009			
55.	2007-01-PCT-JP	ADA	F	PCT/US08/60805	JP	4/18/2008-INT			
56.	2007-01-PCT-BR	ADA	F	PCT/US08/60805	BR	4/18/2008-INT			
57.	2007-01-PCT-CA	ADA	F	2684750	CA	4/18/2008-INT 10/20/2009			
58.	2007-01-PCT-MX	ADA	F	PCT/US08/60805	MX	4/18/2008-INT			
59.	2007-01-PCT-NZ	ADA	F	PCT/US08/60805	NZ	4/18/2008-INT			

IR	Y11	SBJ	STAT	APNO	COIN	APDA	PATNO	PATDA	COMMENTS
60.	2007-01-PCT-KR	ADA	F	10-20097023241	KR	4/18/2008-INT 11/06/2009			
61.	2007-01-PCT-IL	ADA	F	201592	IL	4/18/2008-INT			
62.	2007-01-PCT-IN	ADA	F	1928/MUMNP/2009	IN	4/18/2008-INT			
63.	2007-01-PCT-CN	ADA	F	PCT/US08/60805	CN	4/18/2008-INT			
64.	2007-01-PCT-RU	ADA	F	2009142844	RU	4/18/2008-INT 11/11/2009			
65.	2007-01-TW	ADA	F	97114406	TW	4/18/2008			
66.	2007-01-U	ADA	F	12/105,913	US	4/18/2008			
67.	2007-05	MISC	G	11/780,292	US	7/19/2007	7,584,675	9/8/2009	
68.	2007-13-P	ADA	X	61/017,239	US	12/28/2007			Expired
69.	2007-13-U	ADA	F	12/344,070	US	12/24/2008			
70.	2009-04-P	ASP	F	61/244, 280	US	9/21/2009			

822841.4A-New York Server 4A - MSW
OHS East:160615424.10